Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 12, Issue 17, Pages 2695-2706
Publisher
Informa Healthcare
Online
2011-11-12
DOI
10.1517/14656566.2011.629187
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
- (2011) S. Wilgenhof et al. ANNALS OF ONCOLOGY
- CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation
- (2011) Xiong B Wang et al. BMC IMMUNOLOGY
- CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
- (2011) Jianda Yuan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
- (2011) R. R. Huang et al. CLINICAL CANCER RESEARCH
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
- (2011) Gary Borodic et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
- (2011) Michael A. Curran et al. PLoS One
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- Establishment of Antitumor Memory in Humans Using in Vitro-Educated CD8+ T Cells
- (2011) M. O. Butler et al. Science Translational Medicine
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis
- (2010) J. Schoenfeld et al. CANCER RESEARCH
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- Autoimmunity and treatment outcome in melanoma
- (2010) Marna G Bouwhuis et al. CURRENT OPINION IN ONCOLOGY
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
- (2010) Le Min et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
- (2010) Karl S Peggs et al. Expert Review of Anticancer Therapy
- CTLA-4 is expressed by human monocyte—derived dendritic cells and regulates their functions
- (2010) Stefania Laurent et al. HUMAN IMMUNOLOGY
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
- (2010) Sara M. Mangsbo et al. JOURNAL OF IMMUNOTHERAPY
- Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
- (2010) Helen Gogas et al. Journal of Translational Medicine
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance
- (2010) V. A. Pedicord et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model
- (2010) Maria R. Sorensen et al. VACCINE
- α-CTLA-4 mAb-associated Panenteritis
- (2009) Darryl A. Oble et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Structure-Function analysis of the CTLA-4 interaction with PP2A
- (2009) Wendy A Teft et al. BMC IMMUNOLOGY
- Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
- (2009) David R. Minor et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
- (2009) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
- (2009) M. A. Curran et al. CANCER RESEARCH
- Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
- (2009) A. Ribas et al. CLINICAL CANCER RESEARCH
- Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4
- (2009) O. Klein et al. CLINICAL CANCER RESEARCH
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Adoptive cell therapy for the treatment of patients with metastatic melanoma
- (2009) Steven A Rosenberg et al. CURRENT OPINION IN IMMUNOLOGY
- T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
- (2009) Natalia Martin-Orozco et al. IMMUNITY
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
- (2009) Willemijn B. Breunis et al. JOURNAL OF IMMUNOTHERAPY
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
- (2009) Mojtaba Akhtari et al. JOURNAL OF IMMUNOTHERAPY
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
- (2009) Erika von Euw et al. Journal of Translational Medicine
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-specific Th17-polarized cells eradicate large established melanoma
- (2008) P. Muranski et al. BLOOD
- Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
- (2008) Ilyssa O. Gordon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
- (2008) C. Menard et al. CLINICAL CANCER RESEARCH
- Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
- (2008) A. Ribas et al. CLINICAL CANCER RESEARCH
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
- Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
- (2008) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
- (2008) J. Weber ONCOLOGIST
- Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)
- (2008) A. Ribas ONCOLOGIST
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- (2008) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started